Immune cell pharmaceutical composition and use thereof
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI JUNCELL THERAPEUTICS CO LTD
- Filing Date
- 2025-12-22
- Publication Date
- 2026-06-25
AI Technical Summary
In current immune cell infusion therapy, the use of high doses of fludarabine and cyclophosphamide leads to significant toxic side effects. Furthermore, cyclophosphamide has a long half-life in vivo, which affects the status of peripheral blood cells. Therefore, it is necessary to find alternative drugs to enhance tumor antigen presentation and T cell killing effects.
A combination of gemcitabine and hydroxychloroquine was used to replace high doses of fludarabine and cyclophosphamide in the preparation of a tumor cell killing agent, which increased the expression of type I HLA on the surface of tumor cells and enhanced the killing effect of T cells on tumors.
It effectively enhances the presentation of tumor antigens, strengthens the killing effect of T cells on tumors, reduces the toxic side effects of drugs, and improves the safety and effectiveness of treatment.
Smart Images
Figure CN2025144385_25062026_PF_FP_ABST